Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness ...

Clinuvel Pharmaceuticals (ASX:CUV) has reported encouraging preliminary results from its second study of afamelanotide in ...

HealthDay News — For patients with ischemic stroke, tenecteplase seems to be ... included for 79,550 patients treated with intravenous thrombolysis, of whom 11.9% and 88.1% received tenecteplase ...

Critical Stroke Care Less Likely in Disadvantaged Areas Hospitals serving disadvantaged communities are less likely to administer IV thrombolysis for stroke, compared with hospitals in more ...

account for over half of stroke patients. The benefit of IV thrombolytics (IVT) is less clear in this population. Previous trials, including the ARAMIS trial (Antiplatelet vs r-tPA for Acute Mild ...

The signs of a dangerous blood clot can vary depending on its location. Some people may also not experience any symptoms.

Aster MIMS achieves Comprehensive Stroke Center accreditation from the American Heart Association, enhancing advanced stroke ...